Consequently, there is reason to believe that CD13 decrease mediated by Ubenimex suppressed Bcl-2/Cyto-C and the IAP/Smac pathways to activate the caspase-3-mediated apoptotic cascade and promote FOLFOX-induced tumor apoptosis. This evidence concerns the gene BCL2 and neoplasm.